Research programme: neuron targeting stem cell therapeutics - APstem Therapeutics
Latest Information Update: 18 Jan 2022
At a glance
- Originator APstem Therapeutics
- Class Pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Neurodegenerative disorders; Stroke
Most Recent Events
- 03 Jan 2022 APstem Therapeutics in-licenses adult pluripotent stem cell technology from Stanford University worldwide (APstem Therapeutics pipeline, January 2022)
- 03 Jan 2022 Early research in Neurodegenerative disorders in USA (Parenteral) (APstem Therapeutics pipeline, January 2022)
- 03 Jan 2022 Early research in Stroke in USA (Parenteral) (APstem Therapeutics pipeline, January 2022)